Inclusion Criteria:

- histologically confirmed adenocarcinoma of the prostate

- currently receiving LHRH agonist

- Anti-androgen oral therapy is permitted but will be discontinued upon enrollment

- PSA > 2 ng/ml

- rising PSA despite LHRH agonist

- patients may or may not have clinical evidence off metastases. If metastases are
present, they must be asymptomatic and in bone or lymph node only

- Prior chemotherapy allowed

- ECOG performance status 0-1

Exclusion Criteria:

- Patients with a history of other active malignancies, except: adequately treated
non-melanoma skin cancer, superficial bladder cancer, or other solid tumours
curatively treated with no evidence of disease for ≥ 3 years.

- Other serious illness, psychiatric or medical condition that would not permit the
patient to be managed according to the protocol including: i)Significant
cardiovascular condition including but not limited to: uncontrolled hypertension,
unstable angina, significant congestive heart failure or myocardial infarction, deep
venous thrombosis, pulmonary embolus or cerebrovascular attack within the last 6
months. ii) History of significant neurological disorder that would impair the
ability to obtain consent